Vaccine development for chronic myelogenous leukaemia.
Wong
K K
KK
CML Disease Study Group, Division of Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91024, USA.
Chatterjee
Saswati
S
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001549:Benzamides; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000276:immunology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D012503:Saponins / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001549:Benzamides; D019496:Cancer Vaccines; D010879:Piperazines; D011743:Pyrimidines; D012503:Saponins; C078785:saponin QA-21V1; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl